Ocular adverse events in PD-1 and PD-L1 inhibitors

by James Murray, Howard Streicher, LeAnne Young, Shanda Finnigan, H Nida Sen, Helen X Chen
Published 2021-07-01

Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce

by Maria L. Ascierto, Helen X. Chen, David M. Feltquate, Rachel W. Humphrey, Theresa M. LaVallee, Vanessa M. Hubbard-Lucey, Eric H. Rubin
Published 2020-06-01

Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapy

by Ranee Mehra, Ina Rhee, Naiyer Rizvi, Robert L Ferris, Hussein Tawbi, Matthew D Hellmann, Sarah B Goldberg, Ryan J Sullivan, Helen X Chen, Jong Chul Park, Foluso O Ademuyiwa, Z Alexander Cao
Published 2023-03-01

Phase I pharmacokinetic study of single agent trametinib in patients with advanced cancer and hepatic dysfunction

by Pei Jye Voon, Eric X. Chen, Helen X. Chen, Albert C. Lockhart, Solmaz Sahebjam, Karen Kelly, Ulka N. Vaishampayan, Vivek Subbiah, Albiruni R. Razak, Daniel J. Renouf, Sebastien J. Hotte, Arti Singh, Philippe L. Bedard, Aaron R. Hansen, S. Percy Ivy, Lisa Wang, Lee-Anne Stayner, Lillian L. Siu, Anna Spreafico
Published 2022-02-01